Diagnosis and treatment of gestational trophoblastic disease

Obstetrics and Gynecology

Volumn 103, Issue 6, 2004, Pages 1365-1376

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE;

CHORIOCARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; CURETTAGE; FEMALE; HISTOLOGY; HUMAN; HYDATIDIFORM MOLE; HYSTERECTOMY; INCIDENCE; LIVER TOXICITY; MALIGNANT GESTATIONAL TROPHOBLASTIC DISEASE; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; REPRODUCTION; REVIEW; TREATMENT FAILURE; TROPHOBLASTIC TUMOR;

EID: 16244422302     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Berkowitz RS, Goldstein DP. Gestational trophoblastic diseases. In: Hoskins WJ, Perez CA, Young RC, editors. Principals and practice of gynecologic oncology. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2000. p. 1117-37. (Level III)
2. Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983;145:591-5. (Level III)
3. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and longterm follow-up of 347 patients. Obstet Gynecol 1975;45:1-8. (Level II-3)
4. Soper JT, Lewis JL Jr, Hammond CB. Gestational trophoblastic disease. In: Hoskins WJ, Perez CA, Young RC, editors. Principals and practice of gynecologic oncology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1997. p. 1039-77. (Level III)
5. Feltmate CM, Genest DR, Wise L, Bernstein MR, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001;82:415-9. (Level II-2)
6. Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002;47:460-4. (Level III)
7. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665-71. (Level III)
8. Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995;86:775-9. (Level II-3)
9. Schlaerth JB, Morrow CP, Montz FJ, d'Abling G. Initial management of hydatidiform mole. Am J Obstet Gynecol 1988;158:1299-306. (Level III)
10. Montz FJ, Schlaerth JB, Morrow CP. The natural history of theca lutein cysts. Obstet Gynecol 1988;72:247-51. (Level II-2)
11. Coukos G, Makrigiannakis A, Chung J, Randall TC, Rubin SC, Benjamin I. Complete hydatidiform mole: a disease with a changing profile. J Reprod Med 1999;44:698-704. (Level III)
12. Schlaerth JB, Morrow CP, Rodriguez M. Diagnostic and therapeutic curettage in gestational trophoblastic disease. Am J Obstet Gynecol 1990;162:1465-70; discussion 1470-1. (Level III)
13. Curry SL, Schlaerth JB, Kohorn EI, Boyce JB, Gore H, Twiggs LB, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole. A Gynecologic Oncology Group study. Am J Obstet Gynecol 1989;160:805-9; discussion 809-11. (Level I)
14. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and clinical assessment. Int J Gynecol Cancer 2001;11:73-7. (Level III)
15. Tidy JA, Rustin GJ, Newlands ES, Foskett M, Fuller S, Short D, et al. Presentation and management of choriocarcinoma after nonmolar pregnancy. Br J Obstet Gynaecol 1995;102:715-9. (Level II-3)
16. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of the mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000;78:309-12. (Level II-3)
17. Orr JW Jr, Austin JM, Hatch KD, Shingleton HM, Younger JB, Boots LR. Acute pulmonary edema associated with molar pregnancies: a high-risk factor for development of persistent trophoblastic disease. Am J Obstet Gynecol 1980;136:412-5. (Level III)
18. Twiggs LB, Morrow CP, Schlaerth JB. Acute pulmonary complications of molar pregnancy. Am J Obstet Gynecol 1979;135:189-94. (Level III)
19. Morrow P, Nakamura R, Schlaerth J, Gaddis O Jr, Eddy G. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Am J Obstet Gynecol 1985;151:906-14. (Level II-2)
20. Berkowitz RS, Im SS, Bernstein MR, Goldstein DP. Gestational trophoblastic disease: subsequent pregnancy outcome, including repeat molar pregnancy. J Reprod Med 1998;43:81-6. (Level III)
21. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 1986;67:690-4. (Level I)
22. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001;46:110-6. (Level I)
23. Bristow RE, Shumway JB, Khouzami AN, Witter FR. Complete hydatidiform mole and surviving coexistent twin. Obstet Gynecol Surv 1996;51:705-9. (Level III)
24. Steller MA, Genest DR, Bernstein MR, Lage JM, Goldstein DP, Berkowitz RS. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med 1994;39:147-54. (Level III)
25. Bruchim I, Kidron D, Amiel A, Altaras M, Fejgin MD. Complete hydatidiform mole and a coexistent viable fetus: report of two cases and review of the literature. Gynecol Oncol 2000;77:197-202. (Level III)
26. Matsui H, Sekiya S, Hando T, Wake N, Tomoda Y. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Human Reprod 2000;15:608-11. (Level II-2)
27. Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol 1998;71:325-9. (Level III)
28. Cole LA, Shahabi S, Butler SA, Mitchell H, Newlands ES, Behrman HR, et al. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem 2001;47:308-15. (Level III)
29. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations [published erratum appears in Lancet 2000;356:600]. Lancet 2000;355:712-5. (Level III)
30. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations [published erratum appears in Lancet 2000;356:600]. Lancet 2000;355:712-5. (Level III)
31. Avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test results. ACOG Committee Opinion No. 278. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;100:1057-9. (Level III)
32. DuBeshter B, Berkowitz RS, Goldstein DP, Cramer DW, Bernstein MR. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol 1987;69:390-5. (Level II-3)
33. Hancock BW, Welch EM, Gillespie AM, Newlands ES. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Int J Gynecol Cancer 2000;10:318-22. (Level III)
34. Soper JT, Evans AC, Conaway MR, Clarke-Pearson DL, Berchuck A, Hammond CB. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 1994;84:969-73. (Level II-2)
35. Hammond CB, Weed JC Jr, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol 1980;136:844-58. (Level III)
36. Hammond CB, Borchert LG, Tyrey L, Creasman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol 1973;115:451-7. (Level III)
37. Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992;80:817-20. (Level III)
38. Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988;72:413-8. (Level III)
39. Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. A Gynecologic Oncology Group study. Gynecol Oncol 1990;39:305-8. (Level II-2)
40. Mutch DG, Soper JT, Babcock CJ, Clarke-Pearson DL, Hammond CB. Recurrent gestational trophoblastic disease: experience of the Southeastern Regional Trophoblastic Disease Center Cancer 1990;66:978-82. (Level II-3)
41. Suzuka K, Matsui H, Iitsuka Y, Yamazawa K, Seki K, Sekiya S. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol 2001;97:431-4. (Level II-2)
42. Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery for chemorefactory gestational trophoblastic disease. J Clin Oncol 1994;12:2737-42. (Level II-2)
43. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996;174:1917-23; discussion 1923-4. (Level II-2)
44. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76-9. (Level II-2)
45. Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB. A prospective randomized comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease. A Gynecologic Oncology Group study. Obstet Gynecol 1989; 73:357-62. (Level I)
46. Bagshawe KD, Dent J, Newlands ES, Begent RH, Rustin GJ. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989;96:795-802. (Level III)
47. Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7:900-3. (Level III)
48. Soper JT, Evans AC, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/ cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994;83:113-7. (Level III)
49. Soto-Wright V, Goldstein DP, Bernstein MR, Berkowitz RS. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol Oncol 1997;64:156-9. (Level II-2)
50. Evans AC Jr, Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995;59:226-30. (Level II-2)